Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma (MM) and are associated with more aggressive disease, higher frequency of extramedullary growth and shorter survival. Monotherapy with the BRAF inhibitor vemurafenib has been disappointing in MM. In patients with BRAF-muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ernst, Tina, Aebi, Stefan, Zander, Andrea, Zander, Thilo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Reports: Novel treatment (new drug/interventions; established drug/procedure in new situation)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996037/
https://www.ncbi.nlm.nih.gov/pubmed/35396243
http://dx.doi.org/10.1136/bcr-2021-246264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996037/
https://www.ncbi.nlm.nih.gov/pubmed/35396243
http://dx.doi.org/10.1136/bcr-2021-246264

Ejemplares similares